Diabetes pills may do more than lower blood sugar – could they protect your brain?

NCT ID NCT07244770

Ongoing Knowledge-focused Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study looks at whether two common diabetes drug combinations (SGLT2 inhibitors plus metformin vs. DPP-4 inhibitors plus metformin) affect memory and depression risk in older adults with type 2 diabetes. Researchers will track 300 participants over time using memory tests and depression questionnaires. The goal is to see if one drug combo is linked to better brain health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SGLT2 inhibitors plus metformin, DPP-4 inhibitors plus metformin
What this could lead to: If successful, this could help doctors choose diabetes medications that also protect brain function and mood.
What could go wrong: This is an observational study, not a treatment trial. Results may show associations, not cause and effect. The findings may not apply to younger patients or those on other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCI

Contacts and locations

Locations

Beni Suef Hospital

Banī Suwayf, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.